NEW ENGLAND JOURNAL OF MEDICINE

Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial
Liu QK
View more:
Pubmed
N Engl J Med
Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk
Guan L, Pattinson D, Eisfeld AJ, Wang T, Halfmann PJ, Neumann G, Barnhardt TR, Thompson AC, Swinford AK, Dimitrov KM, Poulsen K and Kawaoka Y
View more:
Pubmed
N Engl J Med
Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply
Jastreboff AM, Ryan DH and Pannacciulli N
View more:
Pubmed
N Engl J Med
Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial
Muskiet MHA and Smits MM
View more:
Pubmed
N Engl J Med
Idiopathic Normal-Pressure Hydrocephalus
Johnson MD and Williams MA
View more:
Pubmed
N Engl J Med
Noninferiority of One HPV Vaccine Dose to Two Doses
Kreimer AR, Porras C, Liu D, Hildesheim A, Carvajal LJ, Ocampo R, Romero B, Gail MH, Cortes B, Sierra MS, Coronado K, Sampson J, Coto C, Dagnall CL, Mora D, Kemp TJ, Zuniga M, Pinto LA, Barrientos G, Schussler J, Estrada Y, Montero C, Avila C, Ruggieri D, Cyr JT, Chanock S, Lowy DR, Schiller JT and Herrero R
Multidose human papillomavirus (HPV) vaccination is efficacious, yet the vaccine has been underused globally. Emerging data suggest that a single dose may provide protection. Whether a single dose of HPV vaccine would provide similar protection to two doses is uncertain.
View more:
Pubmed
N Engl J Med
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes. Reply
Rosenstock J, Cox D and Denning M
View more:
Pubmed
N Engl J Med
Clouded by Smoke
Soled DR, Cernadas M, Ghazani AA, Walker KH and Levy BD
View more:
Pubmed
N Engl J Med
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia
Wang Y, Zhu Z and Liang Y
View more:
Pubmed
N Engl J Med
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia
Fleischman RA
View more:
Pubmed
N Engl J Med
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply
Munir T, Cairns DA and Hillmen P
View more:
Pubmed
N Engl J Med
Digital Exhaust or Digital Gold? The Value of AI-Generated Clinical Visit Transcripts
Goodman KE and Morgan DJ
View more:
Pubmed
N Engl J Med
Evidence to Action - Single-Dose HPV Vaccination and Cervical HPV Infection
Barnabas RV
View more:
Pubmed
N Engl J Med
Simplify or Stratify? The Debate over Medical School Grading Systems
Marwah H, Suri A, Braddock CH, DeWitt DE and Oellrich R
View more:
Pubmed
N Engl J Med
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Xie X and Xuan X
View more:
Pubmed
N Engl J Med
Pegcetacoplan for Treatment of C3 Glomerulopathy and Immune-Complex MPGN
Zand L and Fervenza FC
View more:
Pubmed
N Engl J Med
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Jagarlapudi SP
View more:
Pubmed
N Engl J Med
Empyema Necessitans
Ayoola A and Zejnullahu K
View more:
Pubmed
N Engl J Med
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Nagaoka T
View more:
Pubmed
N Engl J Med
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
Fakhouri F, Bomback AS, Ariceta G, Delmas Y, Dixon BP, Gale DP, Greenbaum LA, Han SH, Isbel N, Le Quintrec M, Licht C, Mastrangelo A, Mizuno M, Neves de Holanda MI, Pickering MC, Remuzzi G, Van De Kar N, Vivarelli M, Walker PD, Wallace D, Zecher D, Francois C, Deschatelets P, Li L, Wang Z, Abad-Franch L, Kinnman N, López-Lázaro L, Szamosi J, Nester CM and
C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (MPGN) generally result in glomerular C3 deposition and irreversible kidney damage. The efficacy and safety of pegcetacoplan, a C3 and C3b inhibitor, in persons with C3 glomerulopathy or primary immune-complex MPGN are unclear.
View more:
Pubmed
N Engl J Med
A Threat to Evidence-Based Vaccine Policy and Public Health Security at the FDA
Califf RM, von Eschenbach AC, Friedman MA, Giroir BP, Gottlieb S, Hamburg MA, Henney JE, Kessler DA, McClellan MB, Ostroff SM, Sharpless NE and Woodcock J
View more:
Pubmed
N Engl J Med